title: Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis.
abstract: OBJECTIVE
  Analyse the effects of anti-tumor necrosis factor therapy on serum levels of lipid in patients with rheumatoid arthritis (RA).
  
  
  METHODS
  Twenty-nine patients (26 females, 3 males) with established RA undergoing anti-TNF therapy (n=12, adalimumab; n=11, infliximab; n=6, etanercept) were recruited. Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (TG), and apolipoproteins (apo b and apo a) were assessed at baseline and after 14 weeks of treatment.
  
  
  RESULTS
  The disease activity index score (DAS(28)) was 5.19+/-0.90 and decreased to 3.46+/-0.97 at 16 weeks (p<0.001). There was no change neither in the levels of TC (5.65+/-0.98mmol/l vs 5.78+/-1.06mmol/l; p=0.43), TG (1.40+/-0.79mmol/l vs 1.45+/-0.67mmol/l; p=0.59), HDL-C (1.92+/-0.49mmol/l vs 1.97+/-0.49mmol/l; p=0.36), apo a1 (1.92+/-0.28g/l vs 1.99+/-0.29g/l; p=0.06), and LDL-C (3.41+/-0.91mmol/l vs 3.47+/-0.96mmol/l; p=0.66), nor in apo b (1.126+/-0.302g/l vs 1.13+/-0.28g/l; p=0.89), atherogenic index (3.13+/-1.05 vs 3.09+/-0.89; p=0.69) or the apo b/apo a1 ratio (0.58+/-0.25 vs 0.56+/-0.22; p=0.33).
  
  
  CONCLUSIONS
  The favourable effect of anti-tumor necrosis factor therapy on cardiovascular morbidity is not related to effects on lipid metabolism.
authors: Service de Rhumatologie, Hôpital G. Montpied, Place Henri Dunant, BP 69, 63003 Clermont-Ferrand Cedex 1, France. msoubrier@chu-clermontferrand.fr
authors: Martin
authors: M
authors: Soubrier
authors: Pierre
authors: P
authors: Jouanel
authors: Sylvain
authors: S
authors: Mathieu
authors: David
authors: D
authors: Poujol
authors: Delphine
authors: D
authors: Claus
authors: Jean Jacques
authors: JJ
authors: Dubost
authors: Jean Michel
authors: JM
authors: Ristori
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001053:Apolipoproteins / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept